Effects of losartan on fibrinolytic parameters and von Willebrand factor in Chinese subjects with hypertension: a comparative study versus atenolol.

Author(s): Liu J, Sun NL, Yang J, Huang JH

Affiliation(s): Heart Centre, Peking University People's Hospital, Beijing, China. heartcenter@163.com

Publication date & source: 2009-05, J Int Med Res., 37(3):595-600.

Publication type: Comparative Study; Randomized Controlled Trial

To compare the effects of losartan and atenolol on plasma fibrinolytic parameters and von Willebrand factor (vWF), Chinese subjects with mild-to-moderate hypertension were randomized to receive losartan (50 mg/day; n = 30) or atenolol (50 mg/day; n = 30) for 8 weeks. If target blood pressure (< 140/90 mmHg) was not achieved at week 4, hydrochlorothiazide (12.5 mg/day) was also administered. Plasma levels of tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) and vWF were determined at baseline and after treatment. Between-group baseline characteristics and blood pressure decrease were comparable. Losartan significantly reduced plasma PAI-1 and vWF and PAI-1/tPA ratio. Atenolol significantly increased plasma tPA, but PAI-1, vWF and PAI-1/tPA ratio were unchanged. In conclusion, losartan, but not atenolol improved the fibrinolytic system and reduced plasma vWF levels in Chinese hypertensives.